Keywords
PET/CT
68Ga-FAPI-04
18F-FDG
How to Cite
Abstract
Introduction. The diagnostic advantage of the fibroblast activation protein inhibitor (FAPI) radiopharmaceutical ⁶⁸Ga-FAPI-04 over the well-established tumor-targeting agent ¹⁸F-FDG (¹⁸F-fluorodeoxyglucose) remains inadequately studied in small patient cohorts, with available literature data showing conflicting results.
Aim. To compare the diagnostic performance of 68Ga-FAPI-04 and ¹8F-FDG positron emission tomography/computed tomography (PET/CT) for detecting malignant tumors and their metastases.
Materials and Methods. The study included 66 patients (30 men, 36 women; median age 54 years [range 22–83]) with histologically confirmed malignant neoplasms of various localizations. PET/CT with both tracers (68Ga-FAPI-04 and 18F-FDG PET/CT) was performed before antitumor therapy in 34 patients (52 %) for initial staging and in 32 patients (48 %) for suspected recurrence or metastatic disease. The interval between scans did not exceed seven days.
Results. 68Ga-FAPI-04 demonstrated significantly higher sensitivity than ¹8F-FDG for detecting primary tumors and assessing disease extent (93.9 vs. 77.3 %; p = 0.006). Pathological 68Ga-FAPI-04 uptake was identified in 33/34 primary tumors (97.1 %) compared to 24/34 (70.6 %) with ¹8F-FDG. Total FAP-expressing tumor volume was significantly larger than metabolic tumor volume measured by ¹8F-FDG PET/CT (34.7 [11–75.66] vs. 11.07 [0–49.5]; p=0.021). 68Ga-FAPI-04 showed superior sensitivity for detecting bone (92.6 vs. 85.2 %; p=0.046) and liver metastases (90.2 vs. 68.3 %; p = 0.014). Although lymph node detection sensitivity was higher with 68Ga-FAPI-04 (81.1 vs. 73 %; p = 0.044), it remained size-dependent.
Conclusions. 68Ga-FAPI-04 PET/CT demonstrates superior sensitivity to ¹8F-FDG PET/CT for identifying primary tumors, recurrences, metastatic dissemination, and quantifying total tumor burden.
References
van den Hoven A.F., Keijsers R.G.M., Lam M.G.E.H., et al. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging. 2023; 50: 1014-1027.-DOI: https://doi.org/10.1007/s00259-022-06052-9.
Franco O.E., Shaw A.K., Strand D.W., Hayward S.W. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol. 2010; 21(1): 33-9.-DOI: https://doi.org/10.1016/j.semcdb.2009.10.010.
Liu F., Qi L., Liu B., et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015; 10(3): 1-18.-DOI: https://doi.org/10.1371/journal.pone.0116683.
Shu Q., Deng M., Hu M., et al. The additional role of [68Ga]Ga FAPI 04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG. Eur J Nucl Med Mol Imaging. 2023; 50: 1442-1452.-DOI: https://doi.org/10.1007/s00259-022-06095-y.
Calais J. FAP: The next billion dollar nuclear theranostics target? Journal of Nucl Med. 2020; 61(2): 163-165.-DOI: https://doi.org/10.2967/jnumed.119.241232.
Dendl K., Finck R., Giesel F.L., et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022; 49(2): 721-731.-DOI: https://doi.org/10.1007/s00259-021-05488-9.
Treglia G., Muoio B., Roustaei H., et al. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F]F-FDG in oncology: A systematic review. Int Journal Mol Sci. 2021; 22(20): 11192.-DOI: https://doi.org/10.3390/ijms222011192.
Chen H., Pang Y., Wu J., et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020; 47(8): 1820-1832.-DOI: https://doi.org/10.1007/s00259-020-04769-z.
Lan L., Liu H., Wang Y., et al. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG. Eur J Nucl Med Mol Imaging. 2022; 49(3): 963-979.-DOI: https://doi.org/10.1007/s00259-021-05522-w.
Sahin E., Kus T., Aytekin A., et al. 68Ga-FAPI PET/CT as an alternative to 18F-FDG PET/CT in the imaging of invasive lobular breast carcinoma. J Nucl Med. 2024; 65: 512-519.-DOI: https://doi.org/10.2967/jnumed.123.266798.
Wang H., Zhu W., Ren S., et al. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021; 11: 693640.-DOI: https://doi.org/10.3389/fonc.2021.693640.
Goh V., Sarker D., Osmany S., Cook G.J. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39(6): 1070-9.-DOI: https://doi.org/10.1007/s00259-012-2096-x.
Kamiyama Y., Aihara R., Nakabayashi T., et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg. 2005; 29(11): 1429-35.-DOI: https://doi.org/10.1007/s00268-005-0045-6.
Wu C., Zhang X., Zeng Y., et al. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging. 2022; 50(1): 194-204.-DOI: https://doi.org/10.1007/s00259-022-05955-x.
Guiyou W., Daofeng W., Wupeng Z., et al. Head-to-head comparison of [68Ga]Ga-FAPI PET and [18F]FDG PET in the detection of bone and lymph node metastasis in various cancers: A systematic review and meta-analysis. Eur J Radiol. 2024; 171: 111302.-DOI: https://doi.org/10.1016/j.ejrad.2024.111302.
Pang Y., Zhao L., Luo Z., et al. Comparison of68Ga-FAPI and18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021; 298(2): 393-402.-DOI: https://doi.org/10.1148/radiol.2020203275.
Liu X., Liu H., Gao C., Zeng W. Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis. Front Oncol. 2023; 17(13): 1093861.-DOI: https://doi.org/10.3389/fonc.2023.1093861.
Sollini M., Kirienko M., Gelardi F., et al. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021; 48: 4396-4414.-DOI: https://doi.org/10.1007/s00259-021-05475-0.
Wu J., Wang Y., Liao T., et al. Comparison of the relative diagnostic performance of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the detection of bone metastasis in patients with different cancers. Front Oncol. 2021; 11: 737827.-DOI: https://doi.org/10.3389/fonc.2021.737827.
Виноградова Ю.Н., Ильин Н.В., Тлостанова М.С., Иванова А.А. Метаболический объем опухоли при лимфомах. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021; 4(4): 40-45.-DOI: https://doi.org/10.37174/2587-7593-2021-4-4-40-45. [Vinogradova Yu.N., Ilyin N.V., Tlostanova M.S., Ivanova A.A. Metabolic tumor volume for patients with lymphomas. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2021; 4(4): 40-5.-DOI: https://doi.org/10.37174/2587-7593-2021-4-4-40-45 (In Rus)].
Zhu Z., Cheng K., Yun Z., et al. [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2023; 50: 3425-3438.-DOI: https://doi.org/10.1007/s00259-023-06271-8.
Almangush A., Heikkinen I., Bakhti N., et al. Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Histopathology. 2018; 72(7): 1128-1135.-DOI: https://doi.org/10.1111/his.13481.
Privé B.M., Boussihmad M.A., Timmermans B., et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023; 50(7): 1906-1918.-DOI: https://doi.org/10.1007/s00259-023-06144-0.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Анна Александровна Иванова, Дарья Викторовна Рыжкова, Андрей Алексеевич Станжевский, Ксения Евгеньевна Санарова, Дарья Андреевна Важенина, Алексей Дмитриевич Майстренко, Максим Владимирович Артемов, Дмитрий Николаевич Майстренко